Immuron H1 FY26 global sales jumps 5%
Immuron (NASDAQ:IMRN), an Australian biopharmaceutical company developing hyper-immune bovine colostrum-derived therapies for gastrointestinal and infectious diseases, on Wednesday released its half-year fiscal 2026 results for the period ended December 31, 2025, alongside a strategic reset announcement.











